A clinical study released by MTF Biologics provides more evidence of the clinical utility of Renuva® Allograft Adipose Matrix in treating small-volume aesthetic soft tissue irregularities. Called Injectable Allograft Adipose Matrix Supports Adipogenic Tissue Remodeling in the Nude Mouse and Human, the peer-reviewed study demonstrated sustained volume retention post-injection of allograft adipose matrix into the dorsal wrist, adding further credence to pre-clinical studies that produced positive results.
The study also provides evidence that human allograft adipose matrix with retained endogenous proteins — those that already exist in native adipose tissue — is safe and effective in retaining volume when the matrix interacts with the host cells.
The latest study bolsters the findings of earlier pre-clinical analysis which determined that allograft adipose matrix is suitable for transplantation, acting physiologically like autologous fat and offering an off-the-shelf application without the need for liposuction. These pre-clinical and clinical studies include:
Renuva® Allograft Adipose Matrix will be discussed at the Symposium for Cosmetic Advances and Laser Education (SCALE), May 9-11, 2019 in Nashville, TN. It also will be featured at the American Society for Aesthetic Plastic Surgery (ASAPS) Aesthetics Meeting, May 16-21, 2019 in New Orleans, LA.
For more information on Renuva® Allograft Adipose Matrix, visit: www.myrenuva.com.
About MTF Biologics
MTF Biologics, also known as the Musculoskeletal Transplant Foundation, is a nonprofit organization based in Edison, N.J. It is a consortium comprised of leading organ procurement organizations, tissue recovery organizations and academic medical institutions, and governed by a board of surgeons who are leading experts in tissue transplantation. As the world’s largest tissue bank, MTF Biologics saves and heals lives by honoring donated gifts, serving patients and advancing science. Since its inception in 1987, the organization has received tissue from more than 132,000 donors and distributed more than 8.6 million grafts for transplantation. Through its IIAM subsidiary, it has placed more than 58,000 non-transplantable organs for research. Through its Statline subsidiary, it has managed more than 11.3 million donor referrals. For more information, visit www.mtfbiologics.org.